(5R,8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-13-methyl-17-prop-1-ynyl-1,2,3,4,5,6,8,11,12,13,14,15,16,17-tetradecahydro-7-oxacyclopenta[a]phenanthrene-3-spiro-2'-[1,3]dioxolane-5,17-diol | 930587-83-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (5R,8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-13-methyl-17-prop-1-ynyl-1,2,3,4,5,6,8,11,12,13,14,15,16,17-tetradecahydro-7-oxacyclopenta[a]phenanthrene-3-spiro-2'-[1,3]dioxolane-5,17-diol
• CAS: 930587-83-0
• 化学式: C₃₀H₃₉NO₅
• 分子量: 493.643
• InChiKey: NVSVQPMCZKMPSO-DBLZYBIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.76
• 重原子数：
  36.0
• 可旋转键数：
  2.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  71.39
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (5R,8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-13-methyl-17-prop-1-ynyl-1,2,3,4,5,6,8,11,12,13,14,15,16,17-tetradecahydro-7-oxacyclopenta[a]phenanthrene-3-spiro-2'-[1,3]dioxolane-5,17-diol 在 盐酸 、 水 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 (8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,8,11,12,13,14,15,16,17-decahydro-6H-7-oxacyclopenta[a]phenanthren-3-one
  参考文献：
  名称：

  OXA-STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS

  摘要：

  本发明涉及新颖的7-氧杂雌甾-4,9-二烯-3,17-二酮衍生物，含有它们的药物组合物以及它们在治疗至少受孕激素或糖皮质激素受体调节的疾病和症状中的应用。

  公开号：

  US20070197635A1
• 作为产物：
  描述：

  (8S,13S,14R)-7-oxa-estra-4,9-diene-3,17-dione 在 吡啶盐酸盐 、 碳酸氢钠 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 苯 为溶剂， 反应 22.0h， 生成 (5R,8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-13-methyl-17-prop-1-ynyl-1,2,3,4,5,6,8,11,12,13,14,15,16,17-tetradecahydro-7-oxacyclopenta[a]phenanthrene-3-spiro-2'-[1,3]dioxolane-5,17-diol
  参考文献：
  名称：

  Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists

  摘要：

  A novel series of oxa-steroids 6 derived from (8S, 13S, 14R)-7-oxa-estra-4,9-diene-3,17-dione 1 have been synthesized and identified as potent and selective progesterone receptor antagonists. These novel oxa-steroids showed similar potency to mifepristone. Preliminary SAR study resulted in the most potent 17-phenylethynyl oxa-steroid 6i wih an IC50 of 1.4 nM. In contrast to the equipotent mifepristone toward the progesterone receptor (PR) and glucocorticoid receptor (GR), compound 6i had over 200-fold selectivity for PR over GR. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.062

文献信息

• Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists
  作者：Fu-An Kang、Jihua Guan、Nareshkumar Jain、George Allan、Olivia Linton、Pamela Tannenbaum、Xin Chen、Jun Xu、Peifang Zhu、Joseph Gunnet、Keith Demarest、Scott Lundeen、Zhihua Sui

  DOI：10.1016/j.bmcl.2007.02.013

  日期：2007.5

  Efficient parallel synthesis of novel 7-oxa-steroids 4 has been achieved from the key intermediate 3 via a one-pot four-step sequence. oxa-Steroids 4 with various ortho-, meta-, and para-monosubstituents on the phenyl ring, as well as disubstituted phenyl and heterocycles, were evaluated for progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist activities. SAR study demonstrated that the para-fluorinated substituents on the phenyl ring not only increased the potency for PR in a T47D cell functional assay, but also improved the selectivity over GR in an A549 cell functional assay. The para-fluorophenyl oxa-steroid 41 and the para-trifluoromethylphenyl oxa-steroid 4p were found to be remarkably more potent and more selective PR antagonists than mifepristone, with subnanomolar potency and about 140-fold selectivity over GR. Molecular modeling of the oxa-steroid bound to PR provided meaningful insight for the SAR study. oxa-Steroids 4a and 4b were found to be more efficacious than mifepristone in vivo in a rat uterine complement C3 assay via the oral route, although they were less than or equally potent to mifepristone in the T47D assay. (c) 2007 Elsevier Ltd. All rights reserved.